Are you a patient living in BC affected by PharmaCare’s Biosimilars Initiative?
Please share your experience!
Recently, the BC Government announced policies that require certain patients enrolled in the province’s PharmaCare program to work with their healthcare team to change their prescription from the originator biologic to the biosimilar drug to maintain their PharmaCare coverage (with some exceptions).
Phase One of the policy change, effective May 27, 2019, affects the following patients:
|etanercept||Enbrel®||Brenzys®||Ankylosing Spondylitis Rheumatoid Arthritis|
|Erelzi™||Ankylosing Spondylitis Psoriatic Arthritis Rheumatoid Arthritis|
|infliximab||Remicade®||Inflectra® Renflexis®||Ankylosing Spondylitis Plaque Psoriasis Psoriatic Arthritis Rheumatoid Arthritis|
|insulin glargine||Lantus®||Basaglar™||Diabetes (Type 1 and 2)|
Phase Two of the policy change, effective September 5, 2019, affects the following patients:
|infliximab||Remicade®||Inflectra® Renflexis®||Crohn’s Disease Ulcerative Colitis|
The Biosimilars Working Group is dedicated to ensuring that good outcomes for patients are at the centre of health policy in Canada, specifically in the biologic medication treatment areas.
To help us understand how patients are experiencing the changes to the BC policy, we are inviting patients from all disease areas who are affected by these changes to let us know your personal experience. Your input will help us better support patients who may be affected by similar policy changes in the future, and other places in Canada. For example,
- What are your overall feelings about these changes?
- Do you feel like you have the information and support you need?
- Did you get any questions you have answered?
- If you have switched treatments already, how has this experience been for you so far?
Please share your stories, positive or negative, by emailing email@example.com. We may share your story (anonymously) on our website. Please let us know in your email or post whether you’d prefer that we don’t post your story publicly.
Thank you for sharing your experience with biosimilars!